UK markets close in 29 minutes
  • FTSE 100

    7,498.11
    +58.37 (+0.78%)
     
  • FTSE 250

    20,174.36
    +122.88 (+0.61%)
     
  • AIM

    920.72
    +0.34 (+0.04%)
     
  • GBP/EUR

    1.1860
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.2119
    +0.0049 (+0.40%)
     
  • BTC-GBP

    19,930.58
    +757.54 (+3.95%)
     
  • CMC Crypto 200

    563.60
    +20.72 (+3.82%)
     
  • S&P 500

    4,179.19
    +34.00 (+0.82%)
     
  • DOW

    33,071.67
    +268.20 (+0.82%)
     
  • CRUDE OIL

    88.56
    -0.45 (-0.51%)
     
  • GOLD FUTURES

    1,804.00
    +12.80 (+0.71%)
     
  • NIKKEI 225

    28,249.24
    +73.37 (+0.26%)
     
  • HANG SENG

    20,045.77
    -156.17 (-0.77%)
     
  • DAX

    13,726.66
    +152.73 (+1.13%)
     
  • CAC 40

    6,547.10
    +74.75 (+1.15%)
     

Cardiomyopathies Epidemiology Forecast, 2021-2031

·3-min read
ReportLinker
ReportLinker

Summary Cardiomyopathy is a general term for a collection of diverse conditions of the heart muscle that inhibit the heart muscle’s ability to pump blood. The main forms of cardiomyopathy are dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic right ventricular cardiomyopathy (ARCM).

New York, July 15, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cardiomyopathies Epidemiology Forecast, 2021-2031" - https://www.reportlinker.com/p06292930/?utm_source=GNW


Cardiomyopathies can eventually lead to irregular heartbeats, the backup of blood into the lungs or rest of the body, and heart failure, which can result in sudden cardiac arrest (CDC, 2019).

Epidemiologists relied on the most robust country-specific data for each segmentation covered in this forecast, obtained from scientific studies published in peer-reviewed academic journals, international healthcare agency publications, nationwide registries, and national disease surveillance agencies available at the time of publication.The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of these cardiomyopathies segmented by subtype, sex, and age (under 18 years, 18–29 years, and by 10-year age groups for ages 30 years up to 80 years and older) in these markets.

The diagnosed prevalent cases are further segmented by causes (acquired versus inherited) and ischemic cases (DCM only).

In the 7MM, the diagnosed prevalent cases of cardiomyopathies will increase from 2,268,240 cases in 2021 to 2,852,506 cases in 2031, at an annual growth rate (AGR) of 2.58% per year. The diagnosed prevalent cases of cardiomyopathies in the five major European markets (5EU) (France, Germany, Italy, Spain, and the UK) will increase at an AGR of 1.43%, from 366,582 cases in 2021 to 419,183 cases in 2031. When examining the AGR by individual markets, The analyst estimates that the US will have the highest number of cases of cardiomyopathies in 2031, with 2,385,118 cases at an AGR of 2.87%. Conversely, Japan will have the least number of cases by 2031, with 48,205 cases at a negative AGR of 0.10%.

Scope
- The cardiomyopathies epidemiology report provides an overview of the risk factors, comorbidities, and global and historical trends for cardiomyopathies (DCM, HCM, RCM, and ARCM) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of cardiomyopathies segmented by subtype, sex, and age (under 18 years, 18–29 years, and by 10-year age groups for ages 30 years up to 80 years and older) in these markets. The diagnosed prevalent cases are further segmented by causes (acquired versus inherited) and ischemic cases (DCM only).
- The epidemiology report provides additional clinically relevant segmentations for the diagnosed prevalent cases of cardiomyopathies including subtype specific etiology
- The cardiomyopathies epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in cardiomyopathies.

Reasons to Buy
The Cardiomyopathies Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global cardiomyopathies markets.
- Quantify patient populations in the global cardiomyopathies markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for cardiomyopathies therapeutics in each of the markets covered.
- Understand magnitude of the population with cardiomyopathies by age, sex, etiology, and ischemia (DCM only).
Read the full report: https://www.reportlinker.com/p06292930/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting